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Abstract
Despite the critical importance of TBX5 in normal development and disease, relatively little is known
about the mechanisms by which TBX5 functions in the embryonic heart. Our present studies
demonstrate that TBX5 is necessary to control the length of the embryonic cardiac cell cycle, with
depletion of TBX5 leading to cardiac cell cycle arrest in late G1- or early S-phase. Blocking cell
cycle progression by TBX5 depletion leads to a decrease in cardiac cell number, an alteration in the
timing of the cardiac differentiation program, defects in cardiac sarcomere formation, and ultimately,
to cardiac programmed cell death. In these studies we have also established that terminally
differentiated cardiomyocytes retain the capacity to undergo cell division. We further show that
TBX5 is sufficient to determine the length of the embryonic cardiac cell cycle and the timing of the
cardiac differentiation program. Thus, these studies establish a role for TBX5 in regulating the
progression of the cardiac cell cycle.
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INTRODUCTION
Hyperplastic growth of the vertebrate heart is characterized by two distinct periods of
proliferation: one that occurs during early embryogenesis and a second that takes place
immediately following birth (MacLellan and Schneider, 2000; Olson and Schneider, 2003;
Pasumarthi and Field, 2002). The embryonic phase of cardiac proliferation begins after cardiac
cell commitment, and therefore occurs coincident with, or shortly after, gastrulation, a period
when the cardiac precursor cells are positioned in two populations on both sides of the organizer
or node. Once cells are committed to the cardiac lineage, the two populations of heart precursors
migrate to assume their ultimate position along the anterior-ventral midline of the embryo. It
is during this narrow window of time that the cardiac precursors undergo rapid cell proliferation
to form two epithelial sheets that migrate and fuse, eventually forming the bilaminar heart tube
(Fishman and Chien, 1997; Harvey, 2002; Kolker et al., 2000; Mohun et al., 2003; Mohun et
al., 2000). During the final stages of migration, the cardiac cells decrease DNA synthesis,
gradually withdraw from the cell cycle and initiate terminal differentiation (Pasumarthi and
Field, 2002).
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During the embryonic stage of cell proliferation, the cardiac cells express the first molecular
markers of cardiac development, including Tbx5, Tbx20 and the homolog of the Drosophila
tinman gene, Nkx2.5 (Harvey, 2002; Stennard and Harvey, 2005). Tbx5 is a member of the T-
box family of transcription factors, a family of proteins that are required for normal vertebrate
patterning and differentiation (Papaioannou and Silver, 1998; Showell et al., 2004; Stennard
and Harvey, 2005; Wilson and Conlon, 2002). Clinical studies have provided direct evidence
for a role for human Tbx5 in heart development, with Tbx5 frequently mutated in patients with
the congenital heart disease Holt-Oram syndrome (HOS) (Basson et al., 1997; Li et al., 1997;
Mandel et al., 2005). HOS is a highly penetrant autosomal dominant condition that is associated
with skeletal and cardiac malformations. The HOS cardiac developmental abnormalities
include atrial and ventricular septal defects, as well as conductivity defects and aberrant
chamber formation (Basson et al., 1999; Benson et al., 1996; Newbury-Ecob et al., 1996). A
role for Tbx5 in HOS is supported by the observation that mice heterozygous for mutations in
Tbx5 display many of the cardiac abnormalities associated with human patients suffering from
HOS (Bruneau et al., 2001). Genetic studies of a Tbx5 mutation in zebrafish and TBX5
depletion in Xenopus are also consistent with a role for TBX5 in heart development (Brown et
al., 2005; Garrity et al., 2002; Horb and Thomsen, 1999). The evolutionarily conserved role
for Tbx5 is further emphasized by molecular experiments carried out in tissue culture, zebrafish,
Xenopus, chicken and mouse, all of which show a role for TBX5 transcriptional activity in
regulating the expression of heart-specific genes (Brown et al., 2005; Bruneau et al., 2001;
Garrity et al., 2002; Hatcher et al., 2001; Hiroi et al., 2001; Liberatore et al., 2000; Plageman
and Yutzey, 2004).
Recently, we have shown that depletion of TBX5 in Xenopus leads to profound morphological
defects in the heart, including pericardial edema, loss of circulation and a concomitant decrease
in cardiac cell number (Brown et al., 2005). In the present study, we demonstrate that the
observed decrease in cell number results from defects in embryonic cardiac cell proliferation.
We go on to define the expression pattern of an extensive panel of CDK and cyclin proteins
in early embryonic cardiac tissue, and show that TBX5 depletion leads to a G1/S-phase arrest,
as demonstrated by a dramatic increase in the expression of proteins associated with the cardiac
cell cycle S-phase, including CDC6, cyclin E2, SLBP and PCNA. This suggests that TBX5 is
involved in either G1/S-phase or the early stages of S-phase progression. The G1/S-phase delay
or arrest coincides with a decrease in the embryonic cardiac mitotic index. These events are
associated with an alteration in the timing of the cardiac differentiation program, defects in
cardiac sarcomere formation and ultimately, cardiac programmed cell death. By contrast,
overexpression of Tbx5, which we show also leads to heart-specific defects, results in an
increase in the cardiac mitotic index and has a converse effect on the timing of the cardiac
differentiation program. Collectively, these studies demonstrate that TBX5 is both necessary
and sufficient to determine the length of cardiac G1/S-phase and the timing of the cardiac
differentiation program.
MATERIALS AND METHODS
Embryo culture and microinjection
Xenopus embryos and Xenopus cardiac actin:GFP transgenic offspring (Latinkic et al., 2002)
were prepared and injected as previously described (Wilson and Hemmati-Brivanlou, 1995),
and staged according to Nieuwkoop (Nieuwkoop, 1967). For TBX5-depletion studies, embryos
were injected with TBX5 and control morpholinos as per Brown and coworkers (Brown et al.,
2005). In misexpression studies, capped mRNA for microinjections was generated using the
mMessage in-vitro transcription kit (Ambion) according to the manufacturer’s instructions.
Resulting mRNA was then purified using the RNeasy kit (Qiagen). Embryos were injected
with the stated amount of Tbx5 RNA at the 1-cell stage. Transgenic animals expressing GFP
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under the cardiac actin promoter were a generous gift from Dr Tim Mohun (Latinkic et al.,
2002).
Immunohistochemistry and whole-mount in-situ hybridization
Embryos were prepared for whole-mount immunohistochemistry according to Kolker and
colleagues (Kolker et al., 2000). Briefly, fixed embryos were incubated overnight at 4°C with
an antibody against tropomyosin (Developmental Studies Hybridoma Bank), at a dilution of
1:50. Following washes, the embryos were incubated overnight at 4°C with a Cy3-conjugated
anti-mouse secondary antibody (Sigma) at a dilution of 1:100. For imaging, embryos were
cleared with 2:1 benzyl benzoate: benzyl alcohol and viewed on a Leica MZFLIII fluorescent
dissecting microscope. For immunostaining of histological sections, embryos were collected
at the indicated stages, fixed for 2 hours in 4% paraformaldehyde, and embedded in OCT
cryosectioning medium (Tissue Tek). Cryostat sections (14 μm) were rinsed with wash buffer
(PBS with 1% Triton and 1% heat inactivated calf serum), and incubated at 4°C overnight, as
indicated, with mouse anti-tropomyosin 1:50, mouse anti-troponin 1:20, mouse anti-fibrillin
1:50 (all from Developmental Studies Hybridoma Bank), mouse anti-MHC (Abcam) rabbit
anti-fibronectin 1:50 (Sigma), rabbit anti- Beta-catenin all at 1:1000 (Sigma), rabbit anti-
phosphohistone H3 1:50 (Upstate) and rabbit anti-cleaved caspase 3 1:50 (Cell Signaling). The
sections were rinsed with wash buffer and the appropriate fluorescent conjugated secondary
antibody diluted in wash buffer: anti-mouse-Cy3 1:100 (Sigma), anti-mouse Cy2 1:100
(Jackson), anti-rabbit-Cy3 1:100 (Sigma) and anti-rabbit-FITC 1:150 (Sigma). Samples were
incubated for 30 minutes at room temperature with DAPI (Sigma) to stain nuclei, or phalloidin
conjugated to Alexa 488 (Molecular Probes, 1:1000) to stain actin filaments. The samples were
imaged on a Zeiss LSM410 confocal microscope. Whole-mount in-situ hybridization was
performed as previously described (Harland, 1991).
RT-PCR primers
The primers used and cycle number were as follows.
EF1-α F, CCTGAACCACCCAGGCCAGATTGGTG; EF1-α R,
AGGTTAGTCAGAGAAGCTCTCCACG (Agius et al., 2000); 25 cycles.
MHC F, GCCAACGCGAACCTCTCCAAGTTCCG; MHC R,
GGTCACATTTTATTTCATGCTGGTTAACAGG (Lab designed); 30 cycles.
Muscle actin F, GCTTGTCCCGATCTGAAC; R, TTGCTTGGAGGAGTGTGT (Lab
designed); 30 cycles.
MyoD F, AGGTCCAACTGCTCCGACGGCATGAA; R,
AGGAGAGAATCCAGTTGATGGAAACA (Hopwood et al., 1989); 25 cycles.
Nkx2.5 F, GAGCTACAGTTGGGTGTGTGTGGT; Nkx2.5 R,
GTGAAGCGACTAGGTATGTGTTCA (DeRobertis, unpublished); 25 cycles.
Tropomyosin F, TGGAGATGGCGGAGAAGAAG; tropomyosin R,
GCAGCAAGTGGCAGTCACGA (Charbonnier et al., 2002); 30 cycles.
Troponin I F, GCTGACAGAATGCAGAAG; troponin I R, GAGATTGGCCCGTAGATC
(DeRobertis, unpublished); 30 cycles.
All primers were designed to span introns to enable PCR products amplified from cDNA to
be distinguished from those amplified by remnant genomic DNA.
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RNA was isolated from five embryos per stage per condition using the RNeasy kit (Qiagen)
according to the manufacturer’s instructions. The resulting RNA was quantitiated using a UV
spectrophotometer (Shimadzu UV-1601), and 100 ng of RNA for each reaction was used to
synthesize cDNA with Superscript II reverse transcriptase (Invitrogen). Total reaction volume
for cDNA synthesis was 20 μl. Resulting cDNA (2 μl) was then used as template in PCR
reactions with Taq polymerase. The number of cycles amplified for each primer (shown above)
was determined by running a test PCR reaction and removing an aliquot of each sample after
20, 25, 30 and 35 rounds of amplification to determine the point at which reactions for each
primer pair reached saturation. The cycle number used in subsequent experiments for each
primer was five amplification cycles prior to the saturation point. For each primer pair, 55°C
was used as the annealing temperature.
Western blots
Heart tissue from a minimum of 300 embryos per condition was dissected at stage 33 and snap
frozen. Tissue was homogenized, subjected to SDS-PAGE, and transferred according to
established protocols. Blots were probed overnight at 4°C with antibodies against Cdc6, Cdt1
[gift from M. Coué, both 1:500 (Whitmire et al., 2002)], cyclin E2 (Abcam, 1:500), PCNA
(Zymed, 1:1000), MCM 4 (Abcam, 1:2000), MCM 5 (Abcam 1:400), MCM7 (LabVision,
1:200), Cdk1 (Zymed, 1:1000), Cdk2 (Upstate, 1:1000), cyclin A1, cyclin A2 (Abcam, both
1:1000), SLBP [gift from W. Marzluff, 1:1000 (Wang et al., 1999)], and cyclin B2 [gift from
T. Hunt, 1:500 (Hochegger et al., 2001)]. Blots were rinsed and probed with the appropriate
HRP-conjugated secondary antibody (Jackson, 1:10,000), and detected with ECL. As a loading
control, blots were reprobed with antibodies against Total MEK (Cell Signaling, 1:2000), alpha
tubulin (Abcam, 1:1000) and/or SHP2 (BD Biosciences, 1:2500).
Transmission electron microscopy
Stage 37 embryos were fixed in 2% paraformaldehyde/2.5% gluteraldehyde overnight.
Embryos were post-fixed in ferrocyanide-reduced osmium and embedded in Spurr’s epoxy
resin. Transverse ultra-thin (70 nm) sections were mounted on copper grids, and post-stained
with 4% aqueous uranyl acetate followed by Reynolds’ lead citrate. Sections were imaged with
a LEO EM-910 transmission electron microscope.
RESULTS
TBX5 depletion leads to a decrease in cardiac proliferation
To understand the role of TBX5 in heart development, we depleted TBX5 from Xenopus
embryos using a morpholino-based approach. Results from these studies show that removal of
TBX5 leads to morphologically abnormal hearts and a decrease in cardiac cell number that is
not associated with a block in cardiac specification, commitment, migration or differentiation
(Brown et al., 2005) (Fig. 1A,B). To characterize the phenotype of TBX5-depleted embryos
in more detail, and to determine the precise developmental stage at which TBX5 is required
during cardiogenesis, we carried out histological analyses and cell-counting studies in TBX5
morpholino-injected (T5MO) and control morpholino-injected (CMO) embryos by double-
staining for the cardiac and skeletal muscle marker tropomyosin and with DAPI, to mark cell
nuclei (Fig. 1C–F). All cells throughout the heart for each stage were counted, and quantitative
results are reported in Fig. 1S. There was no significant difference between control and TBX5-
depleted embryos at stage 33 (Fig. 1C,E,S). However, at stage 37 T5MO embryos showed a
significant decrease in cardiac cell number compared with their sibling controls (Fig. 1D,F,S).
The defect in cell number preceded the expression of proposed TBX5 target genes including
atrial naturitic factor (ANF/Nppa) and connexin 40 (Bruneau et al., 2001; Hiroi et al., 2001;
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Small and Krieg, 2000). Therefore, the reduction in cardiac cell number appears to be one of
the primary cardiac defects in TBX5-depleted embryos.
To determine if the decrease in cardiac cell number is due to cell proliferation or programmed
cell death, we analyzed the mitotic index (Fig. 1G–L,T) and apoptosis (Fig. 1M–R,U) at defined
time points during heart development: stage 29, which corresponds to the stage when the heart
field rounds up to begin forming the bilaminar heart tube; stage 33, at which time cardiac
looping is initiated; and stage 37, corresponding to early chamber formation. For these studies
CMO and T5MO embryos at each stage were serial-sectioned through the cardiac regions and
triple immunostained with anti-tropomyosin (Tmy) to mark cardiomyocytes, DAPI to mark
cell nuclei and either anti-phosphohistone H3 (pH3) to mark cells in M-phase (Fig. 1G–L), or
anti-cleaved caspase 3 to mark cells undergoing apoptosis (Fig. 1M–R). In each study all
cardiomyocytes and endocardial cells encompassed by the cardiomyocytes for each heart at
each stage were scored for pH3 or cleaved caspase 3.
CMO embryos showed that the total cardiomyocyte cell numbers underwent a doubling every
four stages, or 9 hours, at room temperature between stages 33 and 37 (Fig. 1G–I,M–O). As
the majority of the cardiomyocytes appeared to be undergoing mitosis (based on serial sections
of multiple embryos at these stages), the embryonic cardiac cell cycle in Xenopus was
approximately 9 hours in length with M-phase lasting approximately 20 minutes, with the
mitotic index gradually decreasing with age (Fig. 1T). We note there was little to no
cardiomyocyte programmed cell death during these stages (Fig. 1U).
Results from these studies clearly show a decrease in the mitotic index of T5MO-derived
embryos relative to CMO embryos at stage 33 (Fig. 1T); however, no significant programmed
cell death was observed until later stages (stage 37; Fig. 1U). As we observed a dramatic
decrease in the mitotic index at a time prior to the decrease in cardiac cell number or increases
in cardiac programmed cell death (Fig. 1S–U), the primary cause of the reduction in cell number
in T5MO cardiac tissue appears to be a decrease in cardiac cell proliferation. Taken together,
the data suggest that the decrease in proliferation resulting from depletion of TBX5 is due to
either a lengthening of the embryonic cardiac cell cycle or, alternatively, a premature exit of
cardiomyocytes from the cell cycle.
TBX5 depletion leads to a cardiac cell cycle delay or arrest in G1/S-phase
Inference from other systems implies that the integration of growth factor signal cascades with
G1/S cell cycle passage is regulated by the cyclin/CDK complexes CDK2/cyclin E, CDK2/
cyclin A and CDK1/cylin D, many of which are expressed in Xenopus in a stage-and tissue-
specific fashion (Vernon and Philpott, 2003). Although much is known about the cardiac cell
cycle during neonatal periods, little is known about the expression of CDKs and cyclins during
the early stages of embryonic heart development. To address this issue, we isolated hearts from
the first stage at which we could anatomically isolate pure cardiac tissue (stage 33). The
resultant tissues were analyzed relative to corresponding whole embryo lysates with an
extensive panel of antibodies specific for individual cyclins and CDKs (Fig. 2A). Results from
this analysis show that Xenopus cardiac tissue at stage 33 expressed cyclin E2, CDC6, PCNA,
SLBP, CDK2, cyclin A2 and CDK1, as well as proteins that are expressed uniformly
throughout the cell cycle, such as MCM4 and MCM7. Although we could detect high levels
of CDT1, cyclin A1, cyclin B2 and MCM5 in stage 33 embryos, we were able to detect little
to no expression of these proteins in the heart (Fig. 2A). However, due to the relative amount
of cardiac tissue to that of whole embryos, we cannot formally rule out the possibility that these
proteins were present at relatively lower amounts. We note that we were unable to identify any
antibody that marked D cyclins in Xenopus. However, previous studies have suggested that
neither of the Xenopus D cyclins, cyclin D1 or D2, are expressed in the heart at these stages
(Vernon and Philpott, 2003).
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We next analyzed cell cycle proteins in heart tissue derived from T5MO and CMO embryos
(Fig. 2B). These studies show that depletion of TBX5 led to a dramatic upregulation of the S-
phase proteins cyclin E2, CDC6 and CDK2, while proteins associated with other cell cycle
phases, cyclin A2 and CDK1, or proteins expressed throughout the cell cycle, such as MCM4
and MCM7, showed no significant differences between T5MO- and CMO-derived heart tissues
(Fig. 2B). Together with the mitotic index data, our results strongly suggest that depletion of
TBX5 led to a prolonged/arrested G1- or S-phase and a concomitant decrease in the proportion
of cardiac cells in M-phase.
To confirm these findings, we also analyzed CMO- and T5MO-derived hearts for the non-
CDK/cyclin S-phase proteins stem loop binding protein (SLBP) and proliferating cell nuclear
antigen (PCNA) (Fig. 2C). Western blots of CMO- and T5MO-derived heart tissue show that
relative to the loading controls SHP2 and total MEK, depleting TBX5 led to an increase in
both SLBP and PCNA levels. Collectively, these results strongly suggest that TBX5 depletion
leads to a delay or block in the G1- or S-phase of the cardiac cell cycle.
Terminally differentiated cardiomyocytes continue to undergo cell division
Our results suggest that TBX5 is required for embryonic cardiac cell cycle progression (Fig.
2) but is not required for cardiac differentiation (e.g. Fig. 1A,B). Thus, terminally differentiated
cardiomyocytes could be undergoing cell division or, alternatively, a subpopulation of
Xenopus cardiomyocytes may undergo cell cycle arrest and terminal differentiation while a
second subpopulation of cardiomyocytes continue to divide and remain in an undifferentiated
state. The former is consistent with studies in chick and mouse that imply that heart tissue is
capable of initiating and maintaining terminal differentiation during a period in which the cells
are still dividing, i.e. not during G1 or G0 arrest (Anversa and Kajstura, 1998;Burton et al.,
1999;Kajstura et al., 2004;McKinsey et al., 2002;Mikawa et al., 1992a;Mikawa et al.,
1992b;Rybkin et al., 2003;Soonpaa and Field, 1998). To directly test the relationship between
the cardiac cell cycle and terminal differentiation in Xenopus embryonic cardiac tissue, we
triple-labeled cardiomyocytes at stage 37 with anti-pH3, DAPI and a panel of antibodies that
detect terminally differentiated cardiomyocytes, including anti-tropomyosin (Tmy), anti-
myosin heavy chain and phalloidin, to mark cardiac actin (Fig. 3). Results from these studies
clearly show that in CMO hearts we are able to detect cardiomyocytes that are undergoing
mitosis yet also co-express all three markers of terminal differentiation (Fig. 3A–D). In
addition, we note that cardiomyocytes expressing tropomyosin, cardiac actin and cardiac
myosin heavy chain (MHC) showed the hallmarks of terminal cardiomyocyte differentiation,
including the assembly of cells into muscle fibers containing A- and Z-bands. Consistent with
findings that fewer cardiac cells in T5MO embryos undergo mitosis (Fig. 1), we were able to
detect very few anti-phosphorylated histone H3-positive cells in T5MO-derived hearts.
However, of the few cells that expressed pH3, these cells, like controls, also co-expressed
markers of cardiomyocyte terminal differentiation, including tropomyosin, actin and MHC
(Fig. 3E–H). Taken together, these data indicate that terminally differentiated cells in both
control and TBX5-depleted embryos retain the capacity to undergo cell division and suggest
that Xenopus cardiac cells during these stages do not arrest in G1 or G0. These data further
suggest that TBX5, although required for cardiac cell cycle progression, is not required to
initiate or maintain cardiac differentiation.
TBX5 is required for the proper timing of the cardiac program
As TBX5 depletion does not block cardiac differentiation, we next addressed whether TBX5
depletion could affect the stage at which cardiac markers are initially expressed. To this end,
we collected equivalently staged T5MO and CMO embryos at all early stages at which Tbx5
has been reported to be expressed: stages 10 through 38 (early gastrula through late tadpole).
In the first series of studies, we carried out RT-PCR with a panel of primers specific for markers
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of cardiac differentiation (cardiac MHC, cardiac troponin and tropomyosin) or skeletal muscle
differentiation (MyoD, skeletal muscle actin) (Fig. 4A). Results showed significant differences
in the timing of cardiac gene expression in T5MO embryos relative to their stage-matched
CMO siblings; T5MO embryos turned on troponin and cardiac MHC at earlier stages than
controls (stage 28 in T5MO versus stage 32 in CMO) but initiated expression of Tmy at later
stages (stage 24 in T5MO versus 22 in CMO). As we did not observe any changes in the timing
at which skeletal muscle markers are expressed, the alteration in timing of differentiation
appears to be specific to cardiac tissue.
To confirm these findings, we carried out whole-mount antibody staining on T5MO and CMO
embryos for tropomyosin. Consistent with the RT-PCR analysis, we observed a delay in the
expression of tropomyosin in T5MO embryos in comparison with CMO embryos (Fig. 4B–I).
As further confirmation that the timing of differentiation is altered in response to TBX5
depletion in vivo, we injected embryos carrying the cardiac actin:GFP transgene (Latinkic et
al., 2002) with T5MO or CMO and monitored skeletal muscle and heart development in living
staged-matched embryos (Fig. 4J–Q). Although we could not detect any alteration in the timing
of GFP expression in skeletal muscle (data not shown), we observed a consistent and significant
delay in the time at which GFP was first expressed in the hearts of the T5MO embryos.
Collectively, these results suggest that control of the cardiac cell cycle by TBX5 leads to an
alteration in the timing of the cardiac program.
TBX5 depletion leads to abnormal sarcomere formation
To determine if cardiomyocyte differentiation in T5MO hearts occurs in all cardiomyocytes
or only in a subset of cells, we analyzed cardiomyocyte differentiation by
immunohistochemistry on cross-sections of CMO- and T5MO-derived tissues (Fig. 5A–H).
Results clearly showed that by stage 37 we could detect staining of troponin T (cTnT), MHC
and Tmy throughout the myocardium of control and T5MO hearts, suggesting that all
cardiomyocytes in T5MO undergo terminal differentiation.
To examine sarcomere and cytoskeletal structure in greater detail, we double-labeled hearts
from CMO and T5MO embryos with the cardiomyocyte marker Tmy and antibodies that
recognize either components of the cardiac extracellular matrix (ECM), fibronectin and
fibrillin, or mark cardiomyocyte polarity, β-catenin (Fig. 5I–N) (Trinh and Stainier, 2004).
This analysis revealed that TBX5 depletion led to hearts with defects in both sarcomere and
ECM development. By contrast to CMO-derived hearts, which form sarcomeres throughout
the myocardium, T5MO hearts form sarcomeres only in cells adjacent to the lumen of heart
(Fig. 5G,H,O,P). Moreover, the sarcomeres that form often lacked A- and Z-bands and
frequently failed to give rise to myofibrils (Fig. 5O,P). These alterations in cardiomyocyte
differentiation coincided with elevated fibronectin deposition, particularly within the dorsal
portion of the T5MO where the heart remains unfused (Fig. 5I,J) and an increase in both
fibronectin and fibrillin deposition on the walls of the heart chamber (Fig. 5I–L). However, we
could detect no alteration in β-catenin expression (Fig. 5M,N). We also noted that at this stage
it appeared that the majority of β-catenin was associated with the myocardial membranes, with
little to no β-catenin in the cytoplasm or nucleus. Taken together, these data suggest that
alteration in cardiac cell cycle progression due to the depletion of TBX5 leads to abnormal
cardiomyocyte and ECM maturation.
To confirm these structural alterations in TBX5-depleted heart tissue, we carried out
ultrastructural analyses on CMO and T5MO hearts by high magnification confocal microscopy
(Fig. 5O,P) and transmission electron microscopy (TEM) (Fig. 5Q–V). High magnification
imaging of cardiac tissue immunostained with Tmy revealed that the cardiac cells in CMO
embryos formed myofibrils that were distributed throughout the myocardium (Fig. 5O). By
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contrast, the myofibrils in T5MO cardiac cells were poorly organized and formed only adjacent
to the cardiac lumen (Fig. 5P).
Consistent with immunostaining for cardiac muscle, we found in transverse TEM sections of
CMO embryos that cardiac muscle bundles were located throughout the myocardium,
positioned in both longitudinal and concentric arrays (Fig. 5Q). By contrast, T5MO hearts
showed far fewer sarcomeres than controls, and the cells bordering the pericardial space of
T5MO hearts, in contrast with those bordering the heart lumen, completely lacked bundles of
cardiac muscle fibers (Fig. 5R,S,V). Moreover, the sarcomeres that formed frequently lacked
distinct A- and Z-bands, and the A-and Z-bands that were present were poorly defined (Fig.
5T,U). This does not appear to represent simply a delay in myofibril formation, as during
normal development myofibrils form throughout the myocardium and do not show any
temporal differences in differentiation between distal and proximal cardiomyocytes (Kolker
et al., 2000) (Y. Langdon and F.L.C., unpublished).
Taken together, our immunohistochemistry and ultrastructural analysis suggest that the G1/S-
phase delay or arrest in TBX5-depleted embryos results in an alteration in the timing of the
cardiac program, leading to asymmetric and aberrant sarcomere formation. Moreover, these
results imply that TBX5 is not required for the onset of cardiac differentiation but is required
to either establish or maintain cardiomyocyte and cytoskeletal architecture.
TBX5 is both necessary and sufficient for the progression of the embryonic cardiac cell cycle
Our analysis of T5MO embryos shows a requirement for TBX5 in embryonic cell cycle
progression and a role in controlling the correct timing of cardiac differentiation. To determine
if TBX5 is sufficient to regulate these two processes, we misexpressed Tbx5 in early
Xenopus embryos (Fig. 6). Although injection of Tbx5 RNA at the single cell stage caused
Tbx5 misexpression throughout the embryo, phenotypic abnormalities were restricted to the
anterior and cardiac regions of the early tadpole (Fig. 6A–C; data not shown). To further
analyze these defects, we carried out whole-mount in-situ hybridization analyses on uninjected
control and Tbx5-injected embryos (Fig. 6D–G; data not shown). Similar to results from TBX5
depletion, this analysis shows that Tbx5 misexpression did not block cardiac commitment,
migration or terminal differentiation, as judged by Nkx2.5 and myosin light chain (MLC)
expression (Fig. 6D–G).
To test if Tbx5 cardiac defects are associated with alteration in the cardiac cell cycle, we serial-
sectioned embryos at stage 37 and stained with the mitotic marker anti-pH3. We found that
Tbx5 misexpression had the opposite effect of depleting TBX5, leading to a two-fold increase
in the cardiac cell mitotic index (Fig. 6H).
To ensure that the increase in mitotic index is tissue-specific, we calculated the mitotic index
in the ventricular zone of the neural tube in the same sections as those containing the heart
tissue, i.e. sections that correspond exactly to the same point along the anterior-posterior axis.
We could not detect a difference between control or Tbx5-misexpressing-derived neural tissue.
Therefore, the increase in mitotic index within appears to be cardiac-specific.
To test whether TBX5 is also sufficient for the correct timing of cardiac differentiation, we
again collected stage-matched embryos from stage 10 to stage 38 and carried out RT-PCR with
primers specific for the early cardiac marker Nkx2.5, and for markers of cardiac and skeletal
muscle differentiation (Fig. 6J). Consistent with our results for the in-situ hybridization
experiment, we found no alteration in Nkx2.5 expression in Tbx5-injected embryos. Results
for the cardiac differentiation markers showed the exact opposite of those for TBX5 depletion:
Tbx5-injected embryos initially expressed Troponin and MHC at later stages than controls
(stage 38 in Tbx-injected embryos versus stage 28 in control embryos) but turned on Tmy at
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earlier stages (stage 16 in Tbx5-injected embryos versus 22 in control embryos). As we did not
observe any changes in the timing at which skeletal muscle markers were expressed, the
alteration in timing of expression again appeared to be specific to cardiac tissue. Collectively,
these studies strongly suggest that TBX5 is both necessary and sufficient to regulate
progression of the embryonic cardiac cell cycle and the timing of the cardiac program.
DISCUSSION
Despite the crucial importance of understanding cell cycle control for both normal development
and disease, relatively little is known about the proteins that regulate these processes in the
embryonic heart. We demonstrate that that TBX5 is both necessary and sufficient to control
embryonic cardiac cell proliferation and cell number by regulating the length of the embryonic
cardiac cell cycle. Our results show that depletion of TBX5 led to a delay or arrest in G1- or
S-phase, as judged by the upregulation of the G1/S-phase-associated proteins and the
concomitant decrease in the cardiac mitotic index. If the arrest was occurring at the S/G2
transition, Cdc6 and Cyclin E2 levels should be equivalent between T5MO and control heart
tissue. Moreover, cyclin A2 and Cdk1 should be significantly elevated in the T5MO hearts.
As our results clearly show that the level of neither protein was altered in the T5MO tissue
relative to the control, our data strongly suggest that the arrest does not occur at S/G2 but at
the G1/S-phase transition. Because cyclins E and A are thought to be expressed sequentially
during S-phase, and because we observed an increase in cyclin E2 but not in cyclin A2, our
results predict that S-phase arrest in TBX5-depleted embryos would occur at the G1/S-phase
transition or in early S-phase. Based on these findings, we propose that depleting TBX5 results
in a prolonged or blocked early S-phase, resulting in fewer rounds of proliferation, in turn
leading to the reduced cardiac cell number we observed in T5MO embryos (Fig. 7).
Past studies have implied that the myocardium undergoes a fixed number of intrinsically
determined cell divisions before entering a postmitotic state and undergoing cardiac
differentiation (Burton et al., 1999). It appears that TBX5 interferes with this autonomous
program by forcing cells into a prolonged or arrested S-phase and thus differentiating without
undergoing a predetermined number of cell divisions. As in the TBX5-depleted embryos and
embryos misexpressing Tbx5 the timing of the cardiac differentiation program was altered
compared to controls, our results imply that proper S-phase progression, and possibly a
determined number of divisions, are required for the proper timing, but not the initiation, of
heart differentiation. Our results further imply that a reduced number of cardiac divisions leads
to a delay in the expression of some markers of terminal differentiation, including cardiac actin
and tropomyosin. By contrast, we note that troponin and MHC were expressed earlier in T5MO
cardiac tissue and later in hearts from embryos misexpressing Tbx5, suggesting that these
markers are controlled in a different fashion from other cardiac differentiation markers.
TBX5 and embryonic cardiac cell cycle control
Like other members of the T-box gene family, TBX5 has been shown to function as a
transcription factor; TBX5 is localized to the nucleus, it binds to DNA in a sequence specific
fashion and it regulates the transcriptional level of its target genes. Our present studies suggest
that at least one of the targets of TBX5 either directly or indirectly functions to control the
progression of the embryonic cardiac cell cycle. What are the mechanisms by which this may
occur? One possibility is that TBX5 could function to induce the expression of a growth factor,
for example EGF or FGF, which in turn is required for cell cycle progression. In the absence
of this growth factor the cell cycle may not proceed through to the completion of G1 (Fig. 7).
Alternatively, TBX5 may function to regulate the expression of a key component of the pre-
replication complex. In the absence of this key component the pre-replication complex may
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not assemble or may not load onto the origins of replication (ORCs), thus blocking DNA
synthesis and hence cell cycle progression (Fig. 7).
Cell cycle progression through G1/S is regulated by members of the E2F family of transcription
factors, the function of which is governed through their interaction with the retinoblastoma
protein (Rb). In its hypophosphorylated state, Rb interacts with E2F, inhibiting its
transcriptional activation activity. Upon Rb phosphorylation, the Rb-E2F interaction is
disrupted and E2F is released and able to activate its downstream genes required for S-phase
entry (Cobrinik, 2005). Thus, one function of TBX5 may be to indirectly regulate the state of
Rb phosphorylation. Finally, TBX5 may function to negatively regulate general cell cycle
inhibitors such as p27Xic (Fig. 7). Our data cannot distinguish between these possibilities, and
the exact molecular pathway by TBX5 functions awaits the identification of TBX5 cell cycle
target genes.
Tbx5 misexpression leads to cardiac-specific defects
We have shown that misexpression of Tbx5 leads to cardiac defects in vivo. This effect
appeared to be specific, as misexpression of other T-box-containing genes does not give a
similar phenotype (Showell et al., 2004). These results demonstrate that the absolute levels of
TBX5 are crucial for normal heart development in vivo; increased levels of TBX5 results in
abnormal heart formation and reduction of TBX5 levels by just half leads to HOS. Interestingly,
the defects we observed with Tbx5 misexpression were specific to the anterior and cardiac
regions of the embryo, with the cardiac defects resembling those seen with Nkx2.5
misexpression (Cleaver, 1996; Tonissen et al., 1994). The similarity between the Tbx5 and
Nkx2.5 overexpression phenotypes raises the possibility that the misexpression phenotype we
observed in TBX5 was due to an upregulation of Nkx2.5. However, a number of our findings
would suggest that this is not the case. Most crucially, we have conducted in-situ hybridization
as well as RT-PCR to examine Nkx2.5 expression in embryos misexpressing Tbx5 during early
stages of early heart development. We have shown that misexpression of Tbx5 did not lead to
altered spatial or temporal patterns or levels of Nkx2.5 expression at any stage. These results
are consistent with our previously published results showing that the loss of TBX5 has no effect
on the temporal or spatial expression of Nkx2.5 (Brown et al., 2005). Therefore, misexpression
of Tbx5 appears to alter the cardiac mitotic index in an Nkx2.5-independent fashion.
Our finding that Tbx5 misexpression resulted in an increased mitotic index differs from two
previous studies implying that Tbx5 expression inhibits cell growth or survival (Hatcher et al.,
2001; Liberatore et al., 2000). However, in these reports Tbx5 is misexpressed after expression
of endogenous Tbx5 is initiated and, consequently, after the commitment and differentiation
of the heart have taken place. Thus, it may be possible that TBX5 has two opposing functions
during development: an early function in regulating cardiac cell cycle progression and a late
function instructing cardiac cells to undergo cell cycle arrest. Alternatively, overexpression of
TBX5 may lead to it binding and activating non-endogenous targets, in particular those of other
T-box genes, such as TBX2, TBX3, TBX18 or TBX20 (Harvey, 2002; Stennard and Harvey,
2005), which may function during the later stages of cardiogenesis to regulate cell cycle exit.
Holt-Oram syndrome
HOS is an autosomal dominant disease arising from haploinsufficiency of TBX5 and is
associated with conduction-system abnormalities, secundum atrial defect and ventricular septal
defects (Basson et al., 1997; Li et al., 1997; Newbury-Ecob et al., 1996). Consistent with these
phenotypic abnormalities, Tbx5 has been shown to be expressed in the atrial wall, the atrial
septa and the atrial aspects of the atrioventricular valves (Hatcher et al., 2000). The role of
TBX5 in heart development is further emphasized by the observation that mice heterozygous
for mutations in Tbx5 display many of the abnormalities described in HOS patients (Bruneau
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et al., 2001). However, the cellular basis for defects in HOS remains unclear. Our results would
suggest that TBX5 functions to regulate the length of the G1/S cycle within the subset of heart
tissues in which it is expressed. In HOS, G1/S-phase would be significantly lengthened or
blocked, leading to a decrease in cell cycle progression and defects in cell proliferation due to
a successive decrease in the number of cell divisions, and ultimately programmed cell death
in the affected regions.
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Fig. 1. TBX5 is required for cardiac proliferation
Whole-mount antibody staining with tropomyosin (Tmy) of stage 37 (A) control morpholino
(CMO) or (B) TBX5 morpholino (T5MO) embryos. Transverse heart sections through (C,E)
stage 33 and (D,F) stage 37 embryos stained with Tmy, to mark cardiac tissue, and DAPI, to
mark cell nuclei; (C,D) CMO-derived tissue; (E,F) T5MO-derived tissue. (G–L) Examples of
proliferating cardiac cells in transverse heart sections from (G–I) CMO and (J–L) T5MO
embryos sectioned through the cardiac region at stages 29, 33 and 37, as indicated. Proliferating
cardiomyocytes are identified as those positive for Tmy (myofibrilis shown as green) and anti-
phosphohistone H3 (pH3; localized to the nucleus and shown in red). (M–R) Examples of
cardiac cells undergoing apoptosis in transverse heart sections from (M–O) CMO and (P–R)
T5MO embryos at stages 29, 33 and 37, as indicated. Apoptotic cardiomyocytes are identified
as those positive for Tmy (myofibrilis shown as green) and anti-cleaved caspase 3 (CC3;
localized to the nucleus and shown in red). Quantification of results from (S) total
cardiomyocyte cell numbers, (T) mitotic index, and (U) programmed cell death. In all cases,
bars represent the average of at least three embryos: CMO, red bar and T5MO, blue bar. Error
bars denote the standard deviation, and * denotes a statistically significant difference (at
P<0.05) between CMO and T5MO embryos at a given stage. Results are derived from a single
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set of experiments, all experiments being repeated at least once with an independent batch of
embryos. Scale bars: 50 μm. a, atrium; i, inflow tract; o, outflow tract; v, ventricle.
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Fig. 2. TBX5 depletion results in dramatic upregulation of proteins associated with G1/S-phase
within the heart
(A) Expression profile of cell-cycle associated proteins, as determined by western blot analysis
performed using lysate from either whole stage 33 embryos (emb), or corresponding heart
tissue (heart). (B) Relative differences in embryonic cardiac CDK and cyclin proteins between
CMO- and T5MO-derived heart tissue (stage 33). Note increased levels of Cyclin E2, CDC6,
CDK2. (C) Relative differences in embryonic cardiac S-phase associated proteins SLBP and
PCNA between CMO- and T5MO-derived heart tissue (stage 33). Colored bars denote the
stage of the cell cycle at which the proteins are expressed, as indicated in the key.
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Fig. 3. Terminally differentiated cardiomyocytes retain the capacity to undergo cell division
Transverse sections of (A–C) CMO or (E–G) T5MO heart tissues at stage 37, showing cells
coexpressing pH3 (red), DAPI (blue) and either (A,E) actin, (B,F) Tmy or (C,G) MHC (all
shown in green). (D) Schematic of a CMO heart displaying the relative positions of each panel.
A and B were imaged from an area corresponding with ‘A,B’; C was imaged from a region
corresponding with ‘C’. (H) Schematic of a T5MO heart displaying the relative positions of
each panel. E corresponds with ‘E’; F and G correspond with ‘F,G’. White arrows denote
sarcomeric bundles. Scale bar: 10 μm. a, atrium; v, ventricle.
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Fig. 4. The timing of the cardiac differentiation program is altered in TBX5-depleted embryos
(A) RT-PCR analysis of the expression of heart-specific isoforms of MHC, troponin and
tropomyosin; and skeletal muscle-specific genes MyoD and muscle actin, throughout early and
mid-tadpole stages of development in CMO (‘C’) and T5MO (‘T’) stage-matched embryos.
All samples are derived from a single batch of eggs, and identical results were achieved in at
least two independent sets of experiments for each marker. EF1-Alpha was used as a loading
control for all RT-PCR reactions. (B–I) Images depicting embryos injected with (B–E) CMO,
or (F–I) T5MO and immunostained for Tmy, showing delayed expression of Tmy in the hearts
of T5MO embryos. Shown are representative sibling embryos imaged at the indicated stages.
White arrows denote expression of Tmy within the heart. (J–Q) Images of living cardiac
actin:GFP transgenic embryos, showing a delay in the onset of cardiac actin expression in the
heart. Representative sibling embryos obtained from a single batch of embryos were injected
with (J–M) CMO or (N–Q) T5MO and imaged at the indicated stages. Shown is a representative
pair of embryos, while identical results were observed in over 50 embryos. White arrows denote
expression of GFP within the heart field.
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Fig. 5. TBX5 depletion leads to a disruption in cardiac myofibril structure
Cardiomyocyte structure in transverse sections through the hearts of (A,C,E,G) CMO or
(B,D,F,H) T5MO stage 37 embryos, as detected by immunostaining for (A,B) cardiac troponin
T (cTNT), (C,D) MHC, (E,F) actin or (G,H) Tmy. (I,K,M) Stage 37 CMO or (J,L,N) T5MO
embryos double-immunostained for tropomyosin (green) and (I,J) fibronectin, (K,L) fibrillin
or (M,N) β-catenin, all shown in red. Note increase in fibrillin staining on the walls of the
chamber of T5MO hearts relative to CMO (compare panel K to L, white arrows) and ectoptic
expression of fibronectin, shown by white arrow, in the dorsal portion of the heart in panel J
relative to panel I. (O,P) High magnification confocal images of hearts from (O) CMO or (P)
T5MO stage 37 embryos. Note that formation of organized cardiac muscle bundles in T5MO
hearts is limited to a single cluster adjacent to the cardiac lumen. (Q–S) Representative
transmission electron micrographs of transverse images of stage 37 embryos taken from (Q)
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CMO cardiac tissue or (R) T5MO cardiac tissue adjacent to the pericardial cavity and (S) T5MO
cardiac tissue adjacent to the cardiac lumen. Cardiac muscle fibrils are shown pseudo-colored
in yellow. Note that sarcomeres in T5MO hearts can only be identified adjacent to the cardiac
lumen (compare R with S) and only found in concentric arrays. By contrast, CMO-derived
hearts show both longitudinal and concentric arrays (compare Q with S). High-magnification
TEM images reveal the ultrastructures of (T) CMO and (U) T5MO cardiac sarcomeres. Arrows
denote A-bands. Note the smaller, non-continuous A-bands in the T5MO-derived sarcomeres
(U). (V) Traces of the heart sections from CMO and T5MO embryos imaged by TEM are
depicted schematically. Yellow circles represent the location of TEM imaging. Scale bars: 50
μm in A–N; 2 μm in Q–S; 0.2 μm in T,U.
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Fig. 6. Tbx5 misexpression leads to changes in cardiac proliferation and morphology
The overall morphology of stage 40 (A) uninjected embryos or (B,C) embryos injected with
increasing amounts of Tbx5 RNA, as indicated. Arrows denote the location of the heart. (D–
G) Whole-mount in-situ hybridization showing expression of (D,E) Nkx2.5 and (F,G) myosin
light chain (MLC) in (D,F) uninjected stage 37 embryos and (E,G) stage-matched embryos
injected with 1 ng of Tbx5 RNA. (H) Tbx5 misexpression leads to an increase in the cardiac
mitotic index at stage 37. Mitotic index was calculated as the percentage of cardiac cells labeled
with pH3. The data represents the mean of at least three different embryos. Error bars denote
the standard deviation, and * denotes a statistically significant difference between Tbx5-
injected and control embryos (at P<0.05). (I) Mitotic index for sections of the neural tube
corresponding to the same position as the heart along the anterior-posterior axis. The data
represents the mean mitotic index of four different embryos per condition, with four sections
analyzed per embryo. Error bars denote the standard deviation. (J) Tbx5 misexpression leads
to an alteration in the timing and order of the cardiac differentiation program. RT-PCR analysis
of the expression of Nkx2.5 as well as heart-specific isoforms of MHC, troponin and
tropomyosin, and skeletal-muscle-specific genes, MyoD and muscle actin, throughout early
and mid-gestation stages of development in control (‘C’) or Tbx5-injected (‘T’) stage-matched
embryos. All samples are derived from a single batch of eggs and identical results were
achieved in at least two independent sets of experiments for each marker. EF1-alpha was used
as a control for all RT-PCR reactions.
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Fig. 7. Model for potential mechanisms by which TBX5 functions to control embryonic cardiac cell
cycle progression
Schematic of embryonic cardiac cell cycle shown in left hand panel and potential roles for
TBX5 in regulating G1/S progression. (1) TBX5 may function to induce the expression of a
growth factor, for example EGF or FGF required for cell cycle G1 progression. (2) TBX5 may
function to regulate E2F activity by controlling the phosphorylation state of pRB. (3) TBX5
could also negatively regulate general cell cycle inhibitors such as p27Xic. (4) Alternatively
TBX5 may function to regulate the expression of a key component of the CDK-cyclin
complexes required for G1/S progression.
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